Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G J Weiss

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|November 12, 2019
Lack of accountability in upholding authorship standards in prominent medical oncology clinical trialsD Y Gui, G J Weiss
Clinical Pharmacology and Therapeutics|April 23, 2010
Hunting the hedgehog pathwayG J Weiss, D D Von Hoff
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancerG J Weiss, R Rosell, F Fossella, et al.
British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell linesG J Weiss, L T Bemis, E Nakajima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasA Patnaik, L J Appleman, A W Tolcher, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|November 12, 2019
Lack of accountability in upholding authorship standards in prominent medical oncology clinical trialsD Y Gui, G J Weiss
Clinical Pharmacology and Therapeutics|April 23, 2010
Hunting the hedgehog pathwayG J Weiss, D D Von Hoff
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 27, 2007
The impact of induction chemotherapy on the outcome of second-line therapy with pemetrexed or docetaxel in patients with advanced non-small-cell lung cancerG J Weiss, R Rosell, F Fossella, et al.
British Journal of Cancer|June 6, 2014
Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myelomaA Patnaik, G J Weiss, K P Papadopoulos, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 29, 2008
EGFR regulation by microRNA in lung cancer: correlation with clinical response and survival to gefitinib and EGFR expression in cell linesG J Weiss, L T Bemis, E Nakajima, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 28, 2016
First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomasA Patnaik, L J Appleman, A W Tolcher, et al.
Pageof 1